Flavius Martin, Gilead EVP of research

Gilead­'s M&A streak car­ries on with buy­out of pri­vate PARP1, au­toim­mune biotech

Gilead’s deal­mak­ing spree, part of bio­phar­ma’s “blis­ter­ing” M&A this year, con­tin­ued on Tues­day with a con­sum­ma­tion of on­col­o­gy and in­flam­ma­tion start­up XinThera.

Af­ter deals for UK start­up Miro­Bio, a Jounce an­ti­body and Tmu­ni­ty — while pass­ing on Pi­o­nyr — Gilead is now fur­ther ex­pand­ing be­yond its HIV prod­ucts with a biotech near­ing the clin­ic with two oral small mol­e­cule PARP1 in­hibitors for var­i­ous tu­mors. Part of the DNA-re­pair­ing en­zyme fam­i­ly, PARP is tar­get­ed by the likes of As­traZeneca’s Lyn­parza and GSK and Tesaro’s Ze­ju­la, but dose-lim­it­ing tox­i­c­i­ties lim­it their use. Mer­ck KGaA, Duke Street Bio and oth­ers are in­ter­est­ed in next-gen moves.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.